Veeva Systems (VEEV) Tops Q1 EPS by 23c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Veeva Systems (VEEV) PT Raised to $304 at BofA Securities
May 29, 2025 5:38 AM EDTBofA Securities analyst Brad Sills raised the price target on Veeva Systems (NYSE: VEEV) to $304.00 (from $254.00) while maintaining a Neutral rating.
The analyst comments "Veeva reported a strong start to FY26, with subscription revenue and normalized billings of $635 million (+19% y/y) and $714... More
Veeva Systems (VEEV) PT Raised to $295 at Stifel
May 29, 2025 5:05 AM EDTStifel analyst David Grossman raised the price target on Veeva Systems (NYSE: VEEV) to $295.00 (from $272.00) while maintaining a Buy rating.
The analyst comments "F1Q revenue significantly outperformed (subscription revenue +19%, +17% total revenue growth), which translated to meaningful billings/margin/EPS outperformance. Both subscription (+19% y/y, 85% of... More
Veeva Systems (VEEV) PT Raised to $210 at Morgan Stanley
May 29, 2025 5:02 AM EDTMorgan Stanley analyst Craig Hettenbach raised the price target on Veeva Systems (NYSE: VEEV) to $210.00 (from $201.00) while maintaining a Underweight rating.
The analyst comments "Why stay Underweight? Veeva deserves credit for navigating through a tumultuous backdrop in Life Sciences that has tripped up... More

